The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...
For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cis ...
Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...
Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...
The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...
AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
The government had issued notifications to reduce basic customs duty (BCD) to zero on these three drugs/formulations, apart ...
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...